公开(公告)号：US09365522B2

公开(公告)日：2016-06-14

申请号：US14633936

申请日：2015-02-27

Applicant: AMGEN INC. ,  TEIJIN PHARMA LIMITED

Inventor： Hilary Plake Beck ,  Shon Keith Booker ,  Howard Bregman ,  Victor J. Cee ,  Nagasree Chakka ,  Timothy D. Cushing ,  Oleg Epstein ,  Brian M. Fox ,  Stephanie Geuns-Meyer ,  Xiaolin Hao ,  Kenta Hibiya ,  Jun Hirata ,  Zihao Hua ,  Jason Human ,  Shinji Kakuda ,  Patricia Lopez ,  Ryota Nakajima ,  Kazuhisa Okada ,  Steven H. Olson ,  Hiroyuki Oono ,  Lewis D. Pennington ,  Kosuke Sasaki ,  Keiko Shimada ,  Youngsook Shin ,  Ryan D. White ,  Ryan P. Wurz ,  Shuyan Yi ,  Xiao Mei Zheng

IPC: C07D231/14 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/14 ,  C07D493/08 ,  C07D413/12 ,  A61K31/4155 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/422

CPC classification number: C07D231/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/14 ,  C07D493/08

Abstract: The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Abstract translation: 本发明涉及具有抑制RORγ活性的新型化合物。 本发明还涉及包含该化合物的药物组合物，该化合物在治疗或预防自身免疫疾病，炎性疾病，代谢疾病或癌症疾病中的用途。

公开(公告)号：US20150266824A1

公开(公告)日：2015-09-24

申请号：US14633936

申请日：2015-02-27

Applicant: AMGEN INC. ,  Teijin Pharma Limited

Inventor： Hilary Plake Beck ,  Shon Keith Booker ,  Howard Bregman ,  Victor J. Cee ,  Nagasree Chakka ,  Timothy D. Cushing ,  Oleg Epstein ,  Brian M. Fox ,  Stephanie Geuns-Meyer ,  Xiaolin Hao ,  Kenta Hibiya ,  Jun Kirata ,  Zihao Hua ,  Jason Human ,  Shinji Kakuda ,  Patricia Lopez ,  Ryota Nakajima ,  Kazuhisa Okada ,  Steven H. Olson ,  Hiroyuki Oono ,  Lewis D. Pennington ,  Kosuke Sasaki ,  Keiko Shimada ,  Youngsook Shin ,  Ryan D. White ,  Ryan P. Wurz ,  Shuyan Yi ,  Xiao Mei Zheng

IPC: C07D231/14 ,  C07D409/12 ,  C07D413/12 ,  C07D405/14 ,  C07D401/14 ,  C07D493/08 ,  C07D401/12 ,  C07D403/12

CPC classification number: C07D231/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/14 ,  C07D493/08

Abstract: The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Abstract translation: 本发明涉及具有抑制RORγ活性的新型化合物。 本发明还涉及包含该化合物的药物组合物，该化合物在治疗或预防自身免疫疾病，炎性疾病，代谢疾病或癌症疾病中的用途。

公开(公告)号：US09051311B2

公开(公告)日：2015-06-09

申请号：US14383880

申请日：2013-03-07

Applicant: AMGEN INC.

Inventor： Thomas Dineen ,  Charles Kreiman ,  Matthew Weiss ,  Stephanie Geuns-Meyer

IPC: C07D401/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  A61K31/47 ,  C07D417/14

CPC classification number: C07D417/12 ,  C07D401/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

Abstract translation: 本发明提供式I化合物或其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav 1.7。 该化合物可用于治疗可通过抑制钠通道（例如疼痛障碍）治疗的疾病。 还提供含有本发明化合物的药物组合物。

公开(公告)号：US20150018352A1

公开(公告)日：2015-01-15

申请号：US14383880

申请日：2013-03-07

Applicant: AMGEN INC.

Inventor： Thomas Dineen ,  Charles Kreiman ,  Matthew Weiss ,  Stephanie Geuns-Meyer

IPC: C07D417/12 ,  C07D401/14 ,  C07D471/04 ,  C07D417/14

CPC classification number: C07D417/12 ,  C07D401/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.

Abstract translation: 本发明提供式I化合物或其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav 1.7。 该化合物可用于治疗可通过抑制钠通道（例如疼痛障碍）治疗的疾病。 还提供含有本发明化合物的药物组合物。